目的：观察康柏西普玻璃体腔注射应用EX-PRESS青光眼引流器植入治疗新生血管性青光眼的疗效。

方法：选择2015-01/2018-01在我院眼科就诊的新生血管性青光眼患者37例37眼，随机分为试验组与对照组，两组在术前均行康柏西普玻璃体腔注射，试验组和对照组分别选择EX-PRESS青光眼引流器植入术和小梁切除术。对比两组术后成功率、最佳矫正视力、眼压、滤过泡、并发症。

结果：术后12mo， 两组手术成功率、BCVA及滤过泡率均无差异(P>0.05)。两组不同时间点眼压比较有差异(F_组间=10.0，P_组间=0.003； F_时间=496.27，P_时间<0.0001)。所有并发症经对症处理后改善。

结论：EX-PRESS青光眼引流器植入联合康柏西普玻璃体腔注射治疗新生血管性青光眼对降低眼压、减少术后并发症有一定的临床价值。

METHODS: From January 2015 to January 2018, 37 patients(37 eyes)with neovascular glaucoma were randomly divided into experimental group and control group. Both groups were treated with conbercept injection into vitreous cavity before operation. EX-PRESS glaucoma drainage device implantation and trabeculectomy were selected in the experimental group and the control group, respectively. The success rate, best corrected visual acuity(BCVA), intraocular pressure, filtering bleb and complications were compared between the two groups.

RESULTS: At 12mo after operation, there was no significant difference in success rate, BCVA and successful filtering bleb between the two groups. There was significant difference in intraocular pressure between the two groups at different time points(F_group=10.0, P_group=0.003; F_time = 496.27, P<0.0001). All complications were improved after symptomatic treatment.

CONCLUSION: EX-PRESS glaucoma drainage device implantation combined with conbercept vitreous injection in treatment of NVG, which has certain clinical value in reducing intraocular pressure and postoperative complications.